This episode we speak with Tim Schlidt, the co-founder of a psychedelic therapeutics investment fund called Palo Santo.

We discuss the future of psychedelics from a biotech perspective. Which substances that are the most likely to receive FDA approval in the near future, and how the biotech sector is getting involved. From MDMA to psilocybin, and even some less common substances you may not have heard of.

Episode Page:

www.moveconsciousness.com/palosanto

Palo Santo Website:

palosanto.vc/